MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and
consolidation chemotherapy alone or in combination with different therapeutic approaches …

The number of cancer survivors continues to increase because of both advances in early
detection and treatment and the aging and growth of the population. For the public health …

The number of cancer survivors continues to increase due to the aging and growth of the
population and improvements in early detection and treatment. In order for the public health …

Purpose Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a high-
risk subtype of childhood ALL characterized by kinase-activating alterations that are …

Background Treatment with rituximab has improved the outcome for patients with non-
Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also …